{
  "abstract": "We read with interest the article ‘Retrospective study of patient characteristics and treatment for mucormycosis in post-COVID-19 population in a tertiary care hospital’ by Lakshmi et al.1 The purpose of their study was to investigate patient cases of mucormycosis that followed COVID-19 infection. In total they identified 33 cases, the majority being men with an average age of 55 years. According to their study, people who received the COVID-19 vaccine had a decreased risk of contracting mucormycosis in comparison to people who did not receive the vaccination. Furthermore, it was shown that those who used steroids had a noticeably higher risk of infection.",
  "authors": [
    {
      "affiliations": [
        "Private academic consultant, Phonhong, Lao People's Democratic Republic"
      ],
      "name": "Hinpetch Daungsupawong"
    },
    {
      "affiliations": [
        "University Centre for Research and Development Department of Pharmaceutical Sciences, Chandigarh University, Mohali, Punjab, India"
      ],
      "name": "Viroj Wiwanitkit"
    }
  ],
  "title": "Comment on: Retrospective study of patient characteristics and treatment for mucormycosis in post-COVID-19 population",
  "uid": "5bbd339d-9294-5bd9-ae08-4e4c79ee0704"
}